🇺🇸 FDA

Company profile · Sponsor

Immunitybio

Immunitybio Ireland Limited

E2736F2 · EMA pharma GB
Pipeline
2
Drugs
0
Patents
0

Quick answer

Immunitybio (E2736F2) is a pharma company. headquartered in GB. listed on EMA. NovaPharmaNews links 2 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E2736F2
Exchange EMA
Company type pharma
Headquarters GB

Pipeline (2)

Search pipeline →

  1. BCG (50mg/instillation) + N-803 (400 μg/instillation)

    Immunitybio

    Non-muscle Invasive Bladder Cancer

    phase 2 mab active

    1 trial

  2. OncoTICE® powder for instillation fluid for intravesical use containing 2-8 x 108 CFU Tice BCG., N-803 (NAI), OncoTICE® 2-8 x 108 vermehrungsfähige Einheiten Pulver zur Herstellung einer Suspension zur intravesikalen Instillation

    Immunitybio

    Non-Muscle Invasive Bladder Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is Immunitybio?

Immunitybio (E2736F2) is a pharma company. headquartered in GB. listed on EMA. NovaPharmaNews links 2 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Immunitybio sponsor?

We track 2 ClinicalTrials.gov-linked programs for Immunitybio, including BCG (50mg/instillation) + N-803 (400 μg/instillation) and 1 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Immunitybio company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.